Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared Cancer Network post on LinkedIn, adding:
“Now at the 2026 National ICE-T Conference, program chair Jose Sandoval Sus, discussed the importance of breaking downs silos to ensure equitable treatment with CAR T-cell therapy and bispecific antibodies.”
Quoting Cancer Network’s post:
“What can be done to improve access to novel immune effector cell therapies?
At the 2026 National ICE-T Conference, program chair Jose Sandoval-Sus discussed the importance of breaking downs silos to ensure equitable treatment with CAR T-cell therapy and bispecific antibodies.”
Other articles featuring Al-Ola Abdallah and Jose Sandoval Sus Sus on OncoDaily.